Amarin (AMRN)
(Delayed Data from NSDQ)
$0.69 USD
-0.02 (-2.64%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $0.68 -0.01 (-0.93%) 6:26 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMRN 0.69 -0.02(-2.64%)
Will AMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMRN
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Other News for AMRN
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Amarin falls on CEO exit and Vascepa coverage update